Payment overview · 2025
General Payments
$366.54
16 reported records · 11 companies
Healthcare provider profile · identity verified
Dharini Sun, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HAMDEN, CT · NPI 1558355743
Verified facts
What the public records show
CMS Open Payments records show Dharini Sun, M.D. received $366.54 in general payments during 2025 across 16 reported records.
Amgen Inc. accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.05 | 19.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.11 | 12.8% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $45.59 | 12.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $37.89 | 10.3% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.92 | 7.3% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $26.81 | 7.3% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $26.14 | 7.1% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.08 | 6.6% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $23.06 | 6.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.25 | 5.5% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $17.64 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $366.54 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $47.89 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $47.11 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.89 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $26.92 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $26.14 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $23.16 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.25 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $17.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
297 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 672 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 464 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 89 |
| Lisinopril | Lisinopril | 341 | 80 |
| Escitalopram Oxalate | Escitalopram Oxalate | 313 | 54 |
| Gabapentin | Gabapentin | 313 | 61 |
| Eliquis | Apixaban | 297 | 35 |
| Trazodone Hcl | Trazodone Hcl | 277 | 58 |
| Furosemide | Furosemide | 272 | 55 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 248 | 82 |
| Potassium Chloride | Potassium Chloride | 223 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 56 |
| Losartan Potassium | Losartan Potassium | 196 | 59 |
| Omeprazole | Omeprazole | 188 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 183 | 30 |
| Mirtazapine | Mirtazapine | 174 | 35 |
| Metformin Hcl | Metformin Hcl | 171 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 139 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 41 |
| Sertraline Hcl | Sertraline Hcl | 124 | 24 |
| Famotidine | Famotidine | 106 | 23 |
| Alendronate Sodium | Alendronate Sodium | 98 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 25 |
| Allopurinol | Allopurinol | 88 | 25 |
| Entresto | Sacubitril/Valsartan | 85 | suppressed |
| Bupropion Xl | Bupropion Hcl | 84 | 19 |
| Divalproex Sodium | Divalproex Sodium | 84 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 84 | 13 |
| Lorazepam | Lorazepam | 83 | 18 |
| Prednisone | Prednisone | 82 | 22 |
| Montelukast Sodium | Montelukast Sodium | 80 | 24 |
| Alprazolam | Alprazolam | 79 | 28 |
| Farxiga | Dapagliflozin Propanediol | 76 | 11 |
| Myrbetriq | Mirabegron | 75 | suppressed |
| Ezetimibe | Ezetimibe | 74 | 16 |
| Meloxicam | Meloxicam | 74 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 18 |
| Carvedilol | Carvedilol | 69 | 15 |
| Spironolactone | Spironolactone | 66 | suppressed |
| Levetiracetam | Levetiracetam | 65 | suppressed |
| Synthroid | Levothyroxine Sodium | 65 | 20 |
| Olanzapine | Olanzapine | 63 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 62 | 32 |
| Lamotrigine | Lamotrigine | 62 | suppressed |
| Simvastatin | Simvastatin | 60 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 14 |
| Risperidone | Risperidone | 58 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 56 | suppressed |
| Mounjaro | Tirzepatide | 56 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 55 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 13 |
| Linzess | Linaclotide | 53 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | suppressed |
| Trulicity | Dulaglutide | 52 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 14 |
| Ozempic | Semaglutide | 49 | 12 |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Atenolol | Atenolol | 47 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 46 | suppressed |
| Baclofen | Baclofen | 45 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 43 | suppressed |
| Carbamazepine | Carbamazepine | 42 | suppressed |
| Jardiance | Empagliflozin | 42 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Tradjenta | Linagliptin | 41 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 40 | 11 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Ketoconazole | Ketoconazole | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 32 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 19 |
| Eszopiclone | Eszopiclone | 34 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 28 | 11 |
| Methylprednisolone | Methylprednisolone | 28 | 25 |
| Azithromycin | Azithromycin | 27 | 27 |
| Lactulose | Lactulose | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 27 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 26 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 14 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Ursodiol | Ursodiol | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 15 |
| Glipizide | Glipizide | 20 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Nystatin | Nystatin | 17 | 14 |
| Risedronate Sodium | Risedronate Sodium | 17 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 17 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 17 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 16 | 12 |
| Bumetanide | Bumetanide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Voriconazole | Voriconazole | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 13 |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Desoximetasone | Desoximetasone | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Rhopressa | Netarsudil Mesylate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $366.54 · 16 records | Amgen Inc. | Bimzelx, EVENITY, INGREZZA, JARDIANCE, KRYSTEXXA, MOUNJARO, NURTEC ODT, PROLIA, STRENSIQ, TREMFYA, TZIELD, UNITHROID, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error